Coya Therapeutics plans open-label extension of Phase 2/3 ALSTARS trial of COYA 302 in ALS

PUBT · 2d ago
Coya Therapeutics plans open-label extension of Phase 2/3 ALSTARS trial of COYA 302 in ALS
  • Coya Therapeutics plans an open-label extension for its Phase 2/3 ALSTARS trial of COYA 302 in ALS.
  • No clinical results were reported; the extension will collect longer-term safety and efficacy information beyond the 48-week period.
  • Start expected in November 2026 as the first cohort completes treatment, driven by investigator and participant requests to continue dosing.
  • Resource shift delays a planned Phase 2 study of COYA 302 in frontotemporal dementia to 2027 from 2H 2026.
  • Cash runway guidance unchanged; existing cash expected to fund operations into the second half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coya Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261014378134) on October 14, 2026, and is solely responsible for the information contained therein.